Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | TSC2 |
Variant | Q371H |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | TSC2 Q371H lies within the TSC1-interacting region of the Tsc2 protein (UniProt.org). Q371H has been identified in sequencing studies (J Thorac Oncol. Vol 13, Issue 10, S512-S513, PMID: 25801821), but has not been biochemically characterized and therefore, its effect on Tsc2 protein function is unknown (PubMed, Oct 2024). |
Associated Drug Resistance | |
Category Variants Paths |
TSC2 mutant TSC2 Q371H |
Transcript | NM_000548.5 |
gDNA | chr16:g.2060807G>T |
cDNA | c.1113G>T |
Protein | p.Q371H |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001114382 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
XM_005255531.4 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
NM_001114382.3 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
NM_001370404.1 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
NM_001370405.1 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
XM_011522637.3 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
XM_017023615 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
NM_001114382.2 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
NM_001406665.1 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
NM_001077183 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
XM_005255531 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
XM_024450413.1 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
NM_021055.3 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
NM_001077183.2 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
XM_011522640.2 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
XM_011522639.2 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
XM_011522639 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
XM_017023616.1 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
XM_005255529 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
NM_000548.4 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
XM_011522637.2 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
XM_011522640 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
XM_011522636.2 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
XM_017023615.1 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
NM_000548 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
XM_005255529.4 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
XM_011522639.3 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
XM_011522636 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
NM_000548.5 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
NM_001363528.2 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
XM_011522636.3 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
NM_001077183.3 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
XM_011522637 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
NM_001406664.1 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
NM_001406663.1 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
XM_017023616 | chr16:g.2060807G>T | c.1113G>T | p.Q371H | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|